Mumbai: After investing in Marquee healthcare, Orbimed, renowned healthcare industry investor, is now expected to invest in Kolkata-based Suraksha Diagnostics. The deal may take place at a stake of $40 m, with its documentation being under process. The company may soon announce the finalizing of the deal, reports TOI.
Suraksha Diagnostics which is a healthcare firm involved in providing pathology and radiology services across the National Capital Region (NCR), Bihar and West Bengal, will be investing the amount in expanding its laboratory network. The diagnostic firm will also invest some of the amount in equipment facilitation.
Panorama Group Suraksha diagnostics has more than 30 centres in the state including polyclinics. It has also added some more services including cardiology, neurology and gastroenterology.
The chairman of Suraksha Diagnostics, Somnath Chatterjee confirmed, ”Yes, we are in talks with OrbiMed and the deal-making is in the final stage.” He added that this deal will be the first one for OrbiMed in country’s eastern region. Investment bank o3 capital is advising on the transaction.
OrbiMed is a $14m firm which was established in 1989 first in New York, while it came in India in 2008. The firm is incumbent in investing across the global; healthcare industry from starting level healthcare firms and ventures to large publicly traded companies. It has invested in several speciality healthcare services within India.
The firms other investments done in India include an array from Laxmi Dental, Strides Shasun, Surya Pediatric Care to KIMS.